Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical …
Background The use of antithrombotic agents, including anticoagulants, antiplatelet agents,
and thrombolytics has increased over the last decade and is expected to continue to rise …
and thrombolytics has increased over the last decade and is expected to continue to rise …
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
AE Burnett, CE Mahan, SR Vazquez, LB Oertel… - Journal of thrombosis …, 2016 - Springer
Venous thromboembolism (VTE) is a serious medical condition associated with significant
morbidity and mortality, and an incidence that is expected to double in the next forty years …
morbidity and mortality, and an incidence that is expected to double in the next forty years …
Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report
Background The risk of stroke is heterogeneous across different groups of patients with atrial
fibrillation (AF), being dependent on the presence of various stroke risk factors. We provide …
fibrillation (AF), being dependent on the presence of various stroke risk factors. We provide …
Reversal agents for current and forthcoming direct oral anticoagulants
Over the past 20 years, there has been a shift from vitamin K antagonists to direct oral
anticoagulants (DOACs), which include the thrombin inhibitor dabigatran and the factor Xa …
anticoagulants (DOACs), which include the thrombin inhibitor dabigatran and the factor Xa …
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri‐procedural/bleeding management
New oral anticoagulants (NOAC) are becoming available as alternatives to warfarin to
prevent systemic embolism in patients with non‐valvular atrial fibrillation and for the …
prevent systemic embolism in patients with non‐valvular atrial fibrillation and for the …
Antidotes for novel oral anticoagulants: current status and future potential
The direct thrombin inhibitor dabigatran and the anti-Xa agents rivaroxaban, edoxaban, and
apixaban are a new generation of oral anticoagulants. Their advantage over the vitamin K …
apixaban are a new generation of oral anticoagulants. Their advantage over the vitamin K …
Management of bleeding with non–vitamin K antagonist oral anticoagulants in the era of specific reversal agents
CT Ruff, RP Giugliano, EM Antman - Circulation, 2016 - ahajournals.org
Vitamin K antagonists are commonly used by clinicians to provide anticoagulation to
patients who have or are at risk of having thrombotic events. In addition to familiarity with the …
patients who have or are at risk of having thrombotic events. In addition to familiarity with the …
Animal models of thrombosis from zebrafish to nonhuman primates: use in the elucidation of new pathologic pathways and the development of antithrombotic drugs
Thrombosis is a leading cause of morbidity and mortality worldwide. Animal models are
used to understand the pathological pathways involved in thrombosis and to test the efficacy …
used to understand the pathological pathways involved in thrombosis and to test the efficacy …
How I treat target-specific oral anticoagulant–associated bleeding
Target-specific oral anticoagulants (TSOACs) that directly inhibit thrombin (dabigatran) or
factor Xa (rivaroxaban, apixaban) are effective and safe alternatives to vitamin K antagonists …
factor Xa (rivaroxaban, apixaban) are effective and safe alternatives to vitamin K antagonists …
[HTML][HTML] Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant …
E Perzborn, S Heitmeier, V Laux, A Buchmüller - Thrombosis Research, 2014 - Elsevier
Introduction Anticoagulation therapies carry a risk of bleeding; reversal agents may be
beneficial in cases of severe bleeding even for anticoagulants with a relatively short half-life …
beneficial in cases of severe bleeding even for anticoagulants with a relatively short half-life …